Tolerating False Positives: Amylyx, FDA, And The Legal Case For Broad Regulatory Flexibility

Amidst bipartisan congressional pressure to approve ALS drugs, Billy Dunn, head of FDA’s neuroscience division, told advisory committee members that the law ‘demands’ flexibility in review of Amylyx’s AMX0035, and he came prepared with the citations.